Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study

Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol, Robert M Califf, For the PURSUIT Investigators, Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol, Robert M Califf, For the PURSUIT Investigators

Abstract

BACKGROUND: Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators in the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and those adjudicated by a central clinical events committee (CEC) to determine the reasons for differences in event rates. METHODS: The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive eptifibatide or placebo. The primary end-point was death or post-enrolment MI at 30 days as assessed by the CEC; this end-point was also constructed using site-reported events. The CEC identified suspected MIs by systematic review of clinical, cardiac enzyme, and electrocardiographic data. RESULTS: The CEC identified 5005 (46%) suspected events, of which 1415 (28%) were adjudicated as MI. The site investigator and CEC assessments of whether a MI had occurred disagreed in 983 (20%) of the 5005 patients with suspected MI, mostly reflecting site misclassification of post-enrolment MIs (as enrolment MIs) or underreported periprocedural MIs. Patients for whom the CEC and site investigator agreed that no end-point MI had occurred had the lowest mortality at 30 days and between 30 days and 6 months, and those with agreement that a MI had occurred had the highest mortality. CONCLUSION: CEC adjudication provides a standard, systematic, independent, and unbiased assessment of end-points, particularly for trials that span geographic regions and clinical practice settings. Understanding the review process and reasons for disagreement between CEC and site investigator assessments of MI is important to design future trials and interpret event rates between trials.

References

    1. The GUSTO-IIb Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775–782. doi: 10.1056/NEJM199609123351103.
    1. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–961. doi: 10.1056/NEJM199404073301402.
    1. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696. doi: 10.1056/NEJM199706123362401.
    1. The Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106.
    1. Califf RM, Abdelmeguid AE, Kuntz R, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251. doi: 10.1016/S0735-1097(97)00506-8.
    1. The PURSUIT Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. N Engl J Med. 1998;339:436–443. doi: 10.1056/NEJM199808133390704.
    1. The CAVEAT Study Group A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med. 1993;329:221–227. doi: 10.1056/NEJM199307223290401.
    1. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention – IMPACT-II. Lancet. 1997;349:1422–1428. doi: 10.1016/S0140-6736(96)10172-0.
    1. The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669–677.
    1. Walter SD, Cook DJ, Guyatt GH, King D, Troyan S, for the Canadian Lung Oncology Group Outcome assessment for clinical trials: how many adjudicators do we need? Contr Clin Trials. 1997;18:27–42. doi: 10.1016/S0197-2456(96)00131-6.
    1. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5:278–285. doi: 10.1016/1047-2797(94)00093-9.
    1. Remington RD. Who should code cause of death in a clinical trial? Contr Clin Trials. 1984;5:241–244. doi: 10.1016/0197-2456(84)90027-8.
    1. Moussa MA, Shafie MZ, Khogali MM, el-Sayed AM, Sugathan TN, Cherian G, Abdel-Khalik AZ, Garada MT, Verma D. Reliability of death certificate diagnoses. J Clin Epidemiol. 1990;43:1285–1295.
    1. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(suppl):786–806.
    1. Graafsma YP, Prins MH, Lensing AW, de Haan RJ, Huisman MV, Buller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost. 1997;78:1189–1192.
    1. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Tardiff BE, Granger CG, Crenshaw BS, DeJong I, Bhapkar M, Lee KL, Deckers J, Simoons ML, Topol EJ, Califf RM, for the PURSUIT Investigators Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Contr Trials Cardiovasc Med. 2001.
    1. Thrombolysis in Myocardial Ischemia (TIMI) Study Group Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Circulation. 1994;89:1545–1556.
    1. The PRISM PLUS Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497. doi: 10.1056/NEJM199805213382102.
    1. The PRISM Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505. doi: 10.1056/NEJM199805213382103.
    1. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina – the CAPTURE study. Lancet. 1997;349:1429–1435. doi: 10.1016/S0140-6736(96)10452-9.
    1. Antman EM, for the TIMI 9B Investigators Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911–922.
    1. The RESTORE Study Group Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445–1453.
    1. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML, for the PURSUIT Investigators Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. Eur Heart J. 2000;21:371–381. doi: 10.1053/euhj.1999.1743.
    1. The EPIC Investigator Group Long-term protection from myocardial ischemic events in a randomized trial of brief inte-grin β3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479–484.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться